Clinical Trial Detail

NCT ID NCT01894451
Title Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Dana-Farber Cancer Institute
Indications

Her2-receptor negative breast cancer

Therapies

Bevacizumab

Age Groups: adult

Additional content available in CKB BOOST